贵州医科大学学报

1997, (04)

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

IL-2联合LAK细胞治疗癌性胸腹水临床分析
Clinical Analysis of Combinative Treatment of IL-2 and LAK cells to Ascites and Hydrothorax Caused by Carcinomas

王仁敏,郭兵,任崇敏,万昌武,张凤莉,钟复光
Wang Renmin,et alDepartment of Cancer,Guiyang Medical College

摘要(Abstract):

白细胞介素2(IL-2)联合淋巴因子活化的杀伤细胞(LAK细胞)胸腹腔内注入治疗癌性胸腹水14例,总有效率71.42%。其中经顺铂胸腹腔内化疗无效后再改用IL-2/LAK治疗的7例中,5例有效。癌性胸水疗效优于腹水。腔内每次注入IL-240~60万U的疗效比剂量低者好。3例每次IL-2/LAK治疗后连续3d用IL-210~20万U/d腔内注入,利于LAK细胞扩增,疗效满意。获CR、PR者Karnofsky(KPS)评分平均提高10~20分。
Injection of IL-2 with LAK cells (IL2/LAK) into abdomen or thorax was used to treat ascites or hydrothorax caused by carcinomas in 14 patients and the total efficiency (CR plus PR) was 7142%.5 of 7 patients who did not react to cisplatin respondid to the treatment of IL2/LAK.This therapy was more effective to hydrothorax (8889%) than that to ascites (40%) brought about by carcinomas.Injection of 400-600 thousand units of IL2 into abdomen or thoracic cavity seemed better than that of lower doses.Continual injection of 100-200 thousand units of IL2 for 3 days following use of IL2/LAK was encouraging since this improves multiplication of LAK cells in the body.The patients who got CR or PR had 10-20 points more than those before this therapy according to KPS.Our observation showed that IL2/LAK had not any serious toxicity and side effects and it's curative effect is reliable and valuable clinically.

关键词(KeyWords): 白细胞介素2,淋巴因子活化的杀伤细胞,癌,胸水,腹水
iuterleubin2;lymphokine activated killer cells;carcinoma;hydrothorax;ascites

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王仁敏,郭兵,任崇敏,万昌武,张凤莉,钟复光
Wang Renmin,et alDepartment of Cancer,Guiyang Medical College

Email:

DOI: 10.19367/j.cnki.1000-2707.1997.04.018

文章评论(Comment):

序号(No.) 时间(Time) 反馈人(User) 邮箱(Email) 标题(Title) 内容(Content)
反馈人(User) 邮箱地址(Email)
反馈标题(Title)
反馈内容(Content)
扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享